Inotuzumab Ozogamicin

奥加伊妥珠单抗

Report date: 2026/04/03 20:03:44
First In Class

Base Information

Drug NameInotuzumab Ozogamicin
Drug Alias Name伊珠单抗奥加米星inotuzumab ozogamicinainotuzumab ozogamicine奥星-艾诺妥珠单抗奥英妥珠单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > AcBut linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Calicheamicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD22 modulatorsDNA synthesis inhibitors
TargetsCD22DNA
Therapy Area/IndicationsNeoplasm, ResidualHematologic NeoplasmsLymphoma, Follicular +[15] 
Global Approved IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryEU
Original Approved Date2017/06/28
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWyeth Pharmaceutical Co LtdCelltech Group plc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncUniversity College LondonCharite University, Berlin, Germany +[9] 
Inactive CompaniesWyeth LlcCristiana SessaWyeth Parenterals
Active IndicationsNeoplasm, ResidualHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse +[13] 
Inactive IndicationsLymphoma, FollicularLymphoma, Non-Hodgkin

Other Information

ATC CodeL01XC26
Related LinksWikipediaDrugBankKEGG